Nu Skin Enterprises, Inc. (NYSE: NUS) is a global beauty and wellness company that develops and distributes premium anti-aging personal care products, nutritional supplements, and beauty device systems under brands like Nu Skin, Pharmanex, and ageLOC. Financials and expansion is looking peak.
Trailing EPS: $2.19 → Trailing P/E: 4.49x
Forward P/E: 6.93x
EV/EBITDA: 2.70x
Net Debt: ~$67M (Total Debt $320M vs. Cash $253M); Debt/Equity ~40%
Book Value/Share: $16.29 → Trading at 0.60x tangible book
Gross Margin: ~73-75% historical; operating margin expansion underway via cost rationalization
Last quarter revenue was $364M, EPS beat consensus at $0.34. Full year revenue is $1.5B, they're growing in Latin America, China and South Korea. They're going to keep growing into 2026, they're expanding more in Asia. They sold their affiliate platform for $250M recently to help their expansion in Asia. Launched a new platform with a good sub model earlier this month.
They're expanding EBITDA margins; share repurchases authorization remaining. Personal care peers trade 15-25x forward earnings; $NUS at sub-7x forward with superior cash generation and lower leverage post-divestiture.
tl;dr: $NUS @ sub-5x trailing / 7x forward, net cash positive post $250M sale, deep value with turnaround leverage.